Developing a universal vaccine to protect against various strains of influenza
Official title: Broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous NHP challenge model
Funded at Osivax Sas · NIH-10935950 · Data updated 2026-11-12
This study is working on a new flu vaccine that could protect against many different strains of the virus, especially during pandemics, by boosting your immune response, and it will be tested in monkeys to see how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Osivax Sas NIH-funded |
| Lab location | 1 site (Paris, France) |
| Project start | September 26, 2023 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $526,307 |
| NIH project number | 5R01AI177376-02 |
| Project ID | NIH-10935950 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals at high risk for influenza complications, such as the elderly, immunocompromised individuals, and healthcare workers.
✕Less likely to help
Patients who are not at risk for influenza or those who have already been vaccinated with current seasonal vaccines may not benefit from this research.
What this research studies
This research aims to create a universal influenza vaccine that can provide broad protection against multiple strains of the virus. It focuses on targeting a highly conserved protein called nucleoprotein (NP) to stimulate a strong immune response, particularly through T-cells. By using a novel technology to enhance the vaccine's effectiveness, the researchers hope to reduce the risk of severe illness and death from influenza, especially during pandemics. The study will involve testing this vaccine approach in a non-human primate model to evaluate its efficacy.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that offers long-lasting protection against various influenza strains, potentially saving millions of lives during pandemics.
How similar studies have gone: Other research has shown promise in developing universal vaccines targeting conserved viral proteins, indicating potential for success with this novel approach.
Where this research is happening
-
Osivax Sas
Paris, France Active
Researchers
- Principal investigator: Nicolas, Florence — Osivax Sas
- Study coordinator: Nicolas, Florence
Related research
Other NIH-funded projects on the same topics.
-
Creating vaccines for influenza and other infectious diseases
This study is all about creating new vaccines to help protect people from the flu and other infections, so patients can look forward to better options for staying healthy.
-
Creating vaccines for human trials against influenza and other infectious diseases
This study is working on creating new vaccines to help protect people from flu and other infectious diseases, including those that could be used in harmful situations, so that everyone can have safer and more effective options to stay healthy.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Surveillance and preparedness for flu and other respiratory pathogens in Kenya
A US-based research grant aims to improve how Kenya detects and prepares for influenza and other respiratory diseases to protect people there and global health.
-
Enhanced Seasonal Influenza Vaccine Targeting Shared and Variable Viral Antigens
A new DNA-based influenza vaccine approach aims to provide both precise protection against circulating strains and broader defense against unexpected strains.
-
How the immune system responds to flu shots and flu infection
This project looks at how adults' immune systems react after flu shots or when they catch the flu to find why some people get better protection than others.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.